Layered Hemostatic Dressing for Fast Sealing and Safe Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing hemostatic agents face challenges such as infection risk, toxicity, poor adhesion, and inadequate sealing and absorption performance, making them inconvenient to use and less effective in surgical applications.
Innovation Solution
A hemostatic dressing comprising a porous matrix layer, a hemostatic layer with polyhydric phenol-containing moieties, and a binding layer to ensure adhesion and prevent separation, utilizing biocompatible polymers that are biodegradable and form a strong hemostatic film on contact with blood.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If fibrin-based hemostatic agents are used, then hemostatic function is achieved, but infection risk increases and applicability to anticoagulant patients is limited
Solution Approach 1:
The patent changes the chemical composition parameters by replacing fibrin-based materials with polyhydric phenol-containing polymers (such as dopamine-modified chitosan or gelatin), fundamentally altering the material's properties to eliminate infection risks while maintaining hemostatic efficacy through different mechanisms (polymer coagulation and adhesion rather than fibrin clot formation)
Solution Approach 2:
The invention uses composite material structures combining polyhydric phenol-containing polymers with biocompatible porous matrices, creating a new material system that integrates multiple functions: hemostasis through phenol polymerization, adhesion to tissue, and biocompatibility through the porous matrix structure, thereby resolving the limitations of single-material fibrin agents
2Strength
If cyanoacrylate-based hemostatic agents are used, then instant adhesion and hemostasis are achieved, but toxic substances are produced during degradation
Solution Approach 1:
The patent changes the chemical degradation parameters by replacing cyanoacrylate polymers with polyhydric phenol-containing polymers that degrade into non-toxic products (such as dopamine, catechol, and their oxidation products), fundamentally altering the degradation pathway from toxic formaldehyde production to benign metabolic intermediates
Solution Approach 2:
The invention converts the potential harm of polymer degradation by selecting polyhydric phenol polymers whose degradation products are naturally occurring in biological systems and can be safely metabolized, thereby transforming a potentially toxic process into a biocompatible degradation pathway
3Object-affected harmful factors
If natural polymer hemostatic agents are used, then biocompatibility is improved, but hemostatic performance and adhesive strength are insufficient
Solution Approach 1:
The patent creates composite materials by chemically modifying natural polymers (chitosan, gelatin) with polyhydric phenol groups, combining the biocompatibility of natural polymers with the enhanced hemostatic and adhesive properties of phenol-containing structures, achieving both biocompatibility and superior performance
Solution Approach 2:
The invention applies local quality modification by introducing polyhydric phenol moieties at specific locations on the polymer chains, creating regions with enhanced adhesion and hemostatic activity while maintaining the overall biocompatible structure of the natural polymer matrix
4Ease of operation
If blood-insoluble sponge-like structures are used, then non-adhesion to surgical instruments is achieved, but separate adhesion means are required and hemostatic performance is poor
Solution Approach 1:
The patent applies local quality differentiation by designing the dressing with distinct functional zones: the outer surface maintains non-adhesive properties for easy instrument handling, while the inner hemostatic layer contains polyhydric phenol polymers that provide strong adhesion to tissue and excellent hemostatic performance upon contact with blood
5Reliability
If blood-soluble membrane structures are used, then adhesion to living tissue is achieved and hemostatic performance is excellent, but adhesion to surgical instruments causes inconvenience and sealing ability is lost
Solution Approach 1:
The invention implements local quality differentiation by creating functionally distinct layers: an outer non-adhesive layer that prevents sticking to surgical instruments, and an inner hemostatic layer with blood-soluble polyhydric phenol polymers that provide excellent adhesion to living tissue and maintain sealing ability at the bleeding site
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The dressing achieves rapid and strong hemostasis, seals blood effectively without sticking to surgical instruments, and is biocompatible, ensuring long-term stability and safe degradation in vivo.
Implementation Method 1
a hemostatic layer which is loaded on the porous matrix layer and comprises a polymer in which moieties having a benzene ring with one or more hydroxyl groups are introduced
Implementation Method 2
The medical products can seal blood from bleeding sites due to their ability to absorb blood
Implementation Method 3
a binding layer which is interposed between the porous matrix layer and the hemostatic layer to prevent the porous matrix layer from being separated from the hemostatic layer
Data Source
AI summary
Provided is a hemostatic dressing. The hemostatic dressing includes: a porous matrix layer including a biocompatible polymer; a hemostatic layer loaded on the porous matrix layer and including a polymer in which polyhydric phenol-containing moieties are introduced; and a binding layer interposed between the porous matrix layer and the hemostatic layer to prevent the porous matrix layer from being separated from the hemostatic layer.